Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer

Biochemical Pharmacology

Volumn 83, Issue 2, 2012, Pages 207-217

  De Wilt, Leonie H A M ^a   Jansen, Gerrit ^a   Assaraf, Yehuda G ^b   Van Meerloo, Johan ^a   Cloos, Jacqueline ^a   Schimmer, Aaron D ^c   Chan, Elena T ^d   Kirk, Christopher J ^d   Peters, Godefridus J ^a   Kruyt, Frank A E ^e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d ONYX PHARMACEUTICALS   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

5 proteasome subunit; Bortezomib; Lung cancer; Mutation; Proteasome inhibitors; Resistance

Indexed keywords

BORTEZOMIB; PROTEASOME; PROTEASOME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PYRAZINES;

EID: 83955162364     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.10.009     Document Type: Article

References (55)

1. J. Adams The proteasome: structure, function, and role in the cell Cancer Treat Rev 29 Suppl. 1 2003 3 9 (Pubitemid 36626287)
2. D. Voges, P. Zwickl, and W. Baumeister The 26S proteasome: a molecular machine designed for controlled proteolysis Annu Rev Biochem 68 1999 1015 1068 (Pubitemid 29449214)
3. K.L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, and L. Dick Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules Cell 78 1994 761 771 (Pubitemid 24294452)
4. A. Hershko Lessons from the discovery of the ubiquitin system Trends Biochem Sci 21 1996 445 449 (Pubitemid 26393737)
5. J. Adams The development of proteasome inhibitors as anticancer drugs Cancer Cell 5 2004 417 421 (Pubitemid 38610244)
6. T.A. Griffin, D. Nandi, M. Cruz, H.J. Fehling, L.V. Kaer, and J.J. Monaco Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits J Exp Med 187 1998 97 104 (Pubitemid 28044824)
7. M. Altun, P.J. Galardy, R. Shringarpure, T. Hideshima, R. LeBlanc, and K.C. Anderson Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells Cancer Res 65 2005 7896 7901 (Pubitemid 41297267)
8. L.J. Crawford, B. Walker, H. Ovaa, D. Chauhan, K.C. Anderson, and T.C. Morris Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132 Cancer Res 66 2006 6379 6386
9. R.Z. Orlowski, and D.J. Kuhn Proteasome inhibitors in cancer therapy: lessons from the first decade Clin Cancer Res 14 2008 1649 1657 (Pubitemid 351469448)
10. D.J. Kuhn, Q. Chen, P.M. Voorhees, J.S. Strader, K.D. Shenk, and C.M. Sun Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 110 2007 3281 3290 (Pubitemid 350106321)
11. S.D. Demo, C.J. Kirk, M.A. Aujay, T.J. Buchholz, M. Dajee, and M.N. Ho Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res 67 2007 6383 6391 (Pubitemid 47037522)
12. H.J. Zhou, M.A. Aujay, M.K. Bennett, M. Dajee, S.D. Demo, and Y. Fang Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J Med Chem 52 2009 3028 3038
13. D. Chauhan, A.V. Singh, M. Aujay, C.J. Kirk, M. Bandi, and B. Ciccarelli A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma Blood 116 2010 4906 4915
14. V. Cheriyath, B.S. Jacobs, and M.A. Hussein Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors Drugs R D 8 2007 1 12 (Pubitemid 46191803)
15. D.J. McConkey, and K. Zhu Mechanisms of proteasome inhibitor action and resistance in cancer Drug Resist Updat 11 2008 164 179
16. D. Chauhan, G. Li, R. Shringarpure, K. Podar, Y. Ohtake, and T. Hideshima Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells Cancer Res 63 2003 6174 6177 (Pubitemid 37255160)
17. S. Lu, J. Yang, X. Song, S. Gong, H. Zhou, and L. Guo Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line J Pharmacol Exp Ther 326 2008 423 431
18. S. Lu, J. Yang, Z. Chen, S. Gong, H. Zhou, and X. Xu Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line Exp Hematol 37 2009 831 837
19. R. Oerlemans, N.E. Franke, Y.G. Assaraf, J. Cloos, I. van Zantwijk, and C.R. Berkers Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood 112 2008 2489 2499
20. M. Ri, S. Iida, T. Nakashima, H. Miyazaki, F. Mori, and A. Ito Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress Leukemia 24 2010 1506 1512
21. J. Sterz, I. von Metzler, J.C. Hahne, B. Lamottke, J. Rademacher, and U. Heider The potential of proteasome inhibitors in cancer therapy Expert Opin Investig Drugs 17 2008 879 895 (Pubitemid 351864325)
22. H. Yang, J.A. Zonder, and Q.P. Dou Clinical development of novel proteasome inhibitors for cancer treatment Expert Opin Investig Drugs 18 2009 957 971
23. T. Li, L. Ho, B. Piperdi, T. Elrafei, F.J. Camacho, and J.R. Rigas Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC) Lung Cancer 68 2010 89 93
24. A.M. Davies, C. Ho, A.S. Metzger, L.A. Beckett, S. Christensen, and M. Tanaka Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer J Thorac Oncol 2 2007 1112 1116 (Pubitemid 350307905)
25. A.M. Davies, K. Chansky, P.N. Lara Jr. , P.H. Gumerlock, J. Crowley, and K.S. Albain Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339) J Thorac Oncol 4 2009 87 92
26. M.P. Fanucchi, F.V. Fossella, R. Belt, R. Natale, P. Fidias, and D.P. Carbone Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer J Clin Oncol 24 2006 5025 5033 (Pubitemid 46631406)
27. P.N. Lara Jr. , M. Koczywas, D.I. Quinn, H.J. Lenz, A.M. Davies, and D.H. Lau Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial J Thorac Oncol 1 2006 126 134 (Pubitemid 47163999)
28. J. Voortman, E.F. Smit, R. Honeywell, B.C. Kuenen, G.J. Peters, and H. van de Velde A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors Clin Cancer Res 13 2007 3642 3651 (Pubitemid 46955128)
29. C. Ceresa, E. Giovannetti, J. Voortman, A.C. Laan, R. Honeywell, and G. Giaccone Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells Mol Cancer Ther 8 2009 1026 1036
30. W. Xue, E. Meylan, T.G. Oliver, D.M. Feldser, M.M. Winslow, and R. Bronson Response and resistance to NF-kB inhibitors in mouse models of lung adenocarcinoma Cancer Discovery 2011 10.1158/2159-8290.CD-11-0073
31. M.C. de Jong, J.W. Slootstra, G.L. Scheffer, A.B. Schroeijers, W.C. Puijk, and R. Dinkelberg Peptide transport by the multidrug resistance protein MRP1 Cancer Res 61 2001 2552 2557 (Pubitemid 32685838)
32. X. Li, T.E. Wood, R. Sprangers, G. Jansen, N.E. Franke, and X. Mao Effect of noncompetitive proteasome inhibition on bortezomib resistance J Natl Cancer Inst 102 2010 1069 1082
33. T. Muchamuel, M. Basler, M.A. Aujay, E. Suzuki, K.W. Kalim, and C. Lauer A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis Nat Med 15 2009 781 787
34. Y.P. Keepers, P.E. Pizao, G.J. Peters, J. van Ark-Otte, B. Winograd, and H.M. Pinedo Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing Eur J Cancer 27 1991 897 900
35. I.V. Bijnsdorp, F.A. Kruyt, S. Gokoel, M. Fukushima, and G.J. Peters Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent Cancer Sci 99 2008 2302 2308
36. I.V. Bijnsdorp, K. Azijli, E.E. Jansen, M.M. Wamelink, C. Jakobs, and E.A. Struys Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells Biochem Pharmacol 80 2010 786 792
37. F. Parlati, S.J. Lee, M. Aujay, E. Suzuki, K. Levitsky, and J.B. Lorens Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome Blood 114 2009 3439 3447
38. S. Elsasser, M. Schmidt, and D. Finley Characterization of the proteasome using native gel electrophoresis Methods Enzymol 398 2005 353 363 (Pubitemid 41578897)
39. R. Toornvliet, B.N. van Berckel, G. Luurtsema, M. Lubberink, A.A. Geldof, and T.M. Bosch Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography Clin Pharmacol Ther 79 2006 540 548 (Pubitemid 43841828)
40. M.A. van der Pol, H.J. Broxterman, J.M. Pater, N. Feller, M. van der Maas, and G.W. Weijers Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia Haematologica 88 2003 134 147 (Pubitemid 37101491)
41. J. Voortman, A. Checinska, G. Giaccone, J.A. Rodriguez, and F.A. Kruyt Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460 Mol Cancer Ther 6 2007 1046 1053 (Pubitemid 46554575)
42. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, et al. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia; doi:10.1038/leu.2011.256.
43. S. Lu, Z. Chen, J. Yang, L. Chen, H. Zhou, and X. Xu The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02 Int J Lab Hematol 32 2010 e123 e131
44. E. Matsuki, Y. Miyakawa, S. Asakawa, Y. Tsukada, T. Yamada, and K. Yokoyama Identification of loss of p16 expression and upregulation of MDR-1 as genetic events resulting from two novel chromosomal translocations found in a plasmablastic lymphoma of the uterus Clin Cancer Res 17 2011 2101 2109
45. H. Minderman, Y. Zhou, K.L. O'Loughlin, and M.R. Baer Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status Cancer Chemother Pharmacol 60 2007 245 255 (Pubitemid 46742540)
46. H. Rumpold, C. Salvador, A.M. Wolf, H. Tilg, G. Gastl, and D. Wolf Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors Biochem Biophys Res Commun 361 2007 549 554 (Pubitemid 47187282)
47. Y. Liu, X. Liu, T. Zhang, C. Luna, P.B. Liton, and P. Gonzalez Cytoprotective effects of proteasome beta5 subunit overexpression in lens epithelial cells Mol Vis 13 2007 31 38 (Pubitemid 46111846)
48. T. Ruckrich, M. Kraus, J. Gogel, A. Beck, H. Ovaa, and M. Verdoes Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells Leukemia 23 2009 1098 1105
49. A.J. Rivett, and A.R. Hearn Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins Curr Protein Pept Sci 5 2004 153 161 (Pubitemid 38647468)
50. A. Busse, M. Kraus, I.K. Na, A. Rietz, C. Scheibenbogen, and C. Driessen Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits Cancer 112 2008 659 670 (Pubitemid 351186207)
51. U. Seifert, L.P. Bialy, F. Ebstein, D. Bech-Otschir, A. Voigt, and F. Schroter Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress Cell 142 2010 613 624
52. M. Groll, C.R. Berkers, H.L. Ploegh, and H. Ovaa Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure 14 2006 451 456 (Pubitemid 43363478)
53. L. Borissenko, and M. Groll 20S proteasome and its inhibitors: crystallographic knowledge for drug development Chem Rev 107 2007 687 717 (Pubitemid 46502369)
54. M. Groll, K.B. Kim, N. Kairies, R. Huber, and C.M. Crews Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of epoxyketone proteasome inhibitors J Am Chem Soc 122 2000 1237 1238 (Pubitemid 30117471)
55. M. Unno, T. Mizushima, Y. Morimoto, Y. Tomisugi, K. Tanaka, and N. Yasuoka The structure of the mammalian 20S proteasome at 2.75 resolution Structure 10 2002 609 618 (Pubitemid 34518706)